BMS Builds Onto HIV Franchise With Once-daily NRTI From Japanese Biotech Oncolys BioPharma
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bristol-Myers Squibb continues to build up its HIV franchise, obtaining global rights for a nucleoside reverse transcriptase inhibitor from Japanese biotech Oncolys BioPharma